for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Merck & Co., Inc.

MRK

Latest Trade

81.15USD

Change

0.00(0.00%)

Volume

9,100

Today's Range

--

 - 

--

52 Week Range

70.89

 - 

85.60

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
81.15
Open
0.00
Volume
9,100
3M AVG Volume
287.03
Today's High
--
Today's Low
--
52 Week High
85.60
52 Week Low
70.89
Shares Out (MIL)
2,531.37
Market Cap (MIL)
205,421.10
Forward P/E
14.08
Dividend (Yield %)
3.20

Next Event

Q3 2021 Merck & Co Inc Earnings Call

Latest Developments

More

Merck Says CDC ACIP Unanimously Votes To Provisionally Recommend Vaxneuvance In Series With Pneumovax As Option For Pneumococcal Vaccination In Appropriate Adults

Gates Foundation Commits Up To $120 Mln To Accelerate Access To COVID-19 Drug For Lower-Income Countries, Calls On Other Donors To Mobilize Resources

Merck Issues Voluntary Nationwide Recall Of Cubicin 500 Mg Due To Presence Of Particulate Matter Identified As Glass Particles

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Merck & Co., Inc.

Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through two segments: Pharmaceutical and Animal Health. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations. The Animal Health segment develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species.

Industry

Biotechnology & Drugs

Contact Info

2000 Galloping Hill Rd

KENILWORTH, NJ

07033-1310

United States

+1.908.7404000

http://www.merck.com/

Executive Leadership

Kenneth C. Frazier

Executive Chairman of the Board

Robert M. Davis

President, Chief Executive Officer, Director

Caroline Litchfield

Chief Financial Officer, Executive Vice President

Franklin K. Clyburn

President, Human Health, Head of Human Health Commercial and Marketing

Dean Y. Li

President - Merck Research Laboratories

Key Stats

2.04 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

42.3K

2019

46.8K

2020

48.0K

2021(E)

48.1K
EPS (USD)

2018

4.340

2019

5.190

2020

5.940

2021(E)

5.765
Price To Earnings (TTM)
42.95
Price To Sales (TTM)
4.36
Price To Book (MRQ)
6.17
Price To Cash Flow (TTM)
25.07
Total Debt To Equity (MRQ)
79.66
LT Debt To Equity (MRQ)
72.18
Return on Investment (TTM)
7.03
Return on Equity (TTM)
5.31

Latest News

Latest News

Indonesia in talks to buy Merck's COVID-19 antiviral pill - minister

Indonesia is "finalising" a deal with Merck & Co to procure its experimental antiviral pills, named molnupiravir, to treat COVID-19 ailments, its health minister said on Monday.

EU regulator starts real-time review of Merck's COVID-19 pill

U.S. drugmaker Merck & Co Inc said on Monday the European Union's drug regulator has initiated a real-time review of its experimental COVID-19 antiviral drug for adults.

BRIEF-Merck Says EU Regulator Has Started Real-Time Review Of Its COVID-19 Pill

* MERCK - EUROPEAN MEDICINES AGENCY HAS INITIATED ROLLING REVIEW FOR MOLNUPIRAVIR, AN INVESTIGATIONAL ORAL MEDICINE FOR COVID-19 TREATMENT

Factbox-Latest on the worldwide spread of the coronavirus

Russia reported a fourth straight daily record of COVID-19 deaths with a week to go before the start of a workplace shutdown ordered by President Vladimir Putin, while Germany's seven-day incidence rate rose sharply over the past week.

Britain secures COVID-19 antivirals from Merck and Pfizer

Britain said on Wednesday it had secured deals for two COVID-19 antivirals, one developed by Merck and the other by Pfizer, which it said could be used to treat patients by the end of the year if regulatory approval is granted.

Gates Foundation to spend $120 million to speed access to generics of Merck COVID-19 pill

The Bill & Melinda Gates Foundation said on Wednesday it would spend up to $120 million to kick-start development of generic versions of Merck & Co's oral COVID-19 treatment to help ensure lower-income countries have equal access to the drug.

Gates Foundation allots $120 mln for poor nations to get COVID-19 drug

The Gates Foundation will allocate up to $120 million to help lower-income countries get an experimental COVID-19 drug being developed by U.S. drugmaker Merck & Co Inc in the battle against coronavirus, it said on Wednesday.

Exclusive-WHO-led programme aims to buy antiviral COVID-19 pills for $10 -document

A World Health Organization-led programme to ensure poorer countries get fair access to COVID-19 vaccines, tests and treatments aims to secure antiviral drugs for patients with mild symptoms for as little as $10 per course, a draft document seen by Reuters says.

Atea plunges after COVID-19 treatment fails to help patients in study

Atea Pharmaceuticals Inc's experimental COVID-19 antiviral pill, being developed with Roche, failed to help patients with mild and moderate COVID-19 in a small study of mostly low-risk patients, driving the U.S. drugmaker's shares down more than 65% on Tuesday.

Merck COVID-19 pill sparks calls for access for lower income countries

The plan to roll out Merck & Co's promising antiviral pill to treat COVID-19 risks repeating the inequities of vaccine distribution, potentially leaving the nations with the greatest need once again at the back of the line, international health groups say.

U.S. FDA advisers to review Merck's oral COVID-19 drug next month

A panel of outside advisers to the U.S. health regulator will meet late next month to discuss whether to authorize Merck & Co's experimental COVID-19 antiviral drug, the agency said on Thursday.

Merck's COVID-19 drug to be reviewed by U.S. FDA advisers- Bloomberg News

The U.S. Food and Drug Administration will send drugmaker Merck & Co's COVID-19 antiviral drug, molnupiravir, to a panel of its outside advisers for a review, Bloomberg News reported on Thursday, citing a person familiar with the plans.

Holocene Advisors says Merck's offer undervalues Acceleron

Investment management firm Holocene Advisors said it will not back Merck & Co's offer to buy Acceleron Pharma Inc for $180 per share, saying it significantly undervalues the drugmaker.

Holocene Advisors says Merck's offer undervalues Acceleron

Investment management firm Holocene Advisors said on Wednesday that Merck & Co's proposed offer of $180 per share for Acceleron Pharma Inc significantly undervalues the company.

EU may consider deal on Merck's COVID pill after approval procedure begins -source

The European Union may consider signing a supply deal with U.S. drugmaker Merck for its experimental COVID-19 pill, but only after the company starts the process of seeking approval for the drug in the bloc, a senior EU official said on Tuesday.

EU may consider deal on Merck's COVID pill after approval procedure begins - source

The European Union may consider signing a supply deal with U.S. drugmaker Merck for its experimental COVID-19 pill, but only after the company starts the process of seeking approval for the drug in the bloc, a senior EU official said on Tuesday.

India's Everest Organics starts making ingredient for Merck's COVID-19 pill

India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.

WHO says it awaits full data from Merck on antiviral pill

The World Health Organization is awaiting full clinical data on the antiviral pill made by Merck & Co Inc to treat mild-to-moderate COVID-19 patients, a WHO spokesperson said on Tuesday, a day after the company said it had applied for U.S. emergency use authorisation.

AstraZeneca antibody cocktail study shows success treating COVID-19

AstraZeneca's antibody cocktail against COVID-19, which has proven to work as a preventative shot in the non-infected, was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.

Merck seeks first U.S. authorization for COVID-19 pill

Merck & Co Inc said on Monday it has applied for U.S. emergency use authorization for its drug to treat mild-to-moderate patients of COVID-19, putting it on course to become the first oral antiviral medication for the disease.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up